ScholarLens Back to search
2011•Medical Journal of Chinese People's HealthRequires access

Clinical analysis of Aripiprazole in the treatment of schizophrenia

Yuewei Li

Open publisher page 0 citations

Abstract

Objective:To observe the adverse events and efficacy of Aripiprazole in the treatment of schizophrenia.Methods:Sixty-four cases of schizophrenia were randomly divided into Aripiprazole group and Risperidone group.The course of treatments was 8 weeks.The therapeutic effects were evaluated by positive and negative symptom scale(PANSS),and side effects were assessed by treatment emergent symptom scale(TESS).Results:The rates of marked improvement in Aripiprazole group and Risperidone group were 78.1% and 75.0% respectively.The extractor-ticospinal(EPS) tract reaction was more severe in risperidone group than in Aripiprazole group.Conclusion:Aripiprazole,as well as Risperidone,is one of effective antipsychotics and less EPS in the treatment of schizophrenia.

About this research paper

What this paper is about

Objective:To observe the adverse events and efficacy of Aripiprazole in the treatment of schizophrenia.Methods:Sixty-four cases of schizophrenia were randomly divided into Aripiprazole group and Risperidone group.The course of treatments was 8 weeks.The therapeutic effects were evaluated by positive and negative symptom scale(PANSS),and side effects were assessed by treatment emergent symptom scale(TESS).Results:The rates of marked improvement in Aripiprazole group and Risperidone group were 78.1% and 75.0% respectively.The extractor-ticospinal(EPS) tract reaction was more severe in risperidone group than in Aripiprazole group.Conclusion:Aripiprazole,as well as Risperidone,is one of effective antipsychotics and less EPS in the treatment of schizophrenia.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To observe the adverse events and efficacy of Aripiprazole in the treatment of schizophrenia.Methods:Sixty-four cases of schizophrenia were randomly divided into Aripiprazole group and Risperidone group.The course of treatments was 8 weeks.The therapeutic effects were evaluated by positive and negative symptom scale(PANSS),and side effects were assessed by treatment emergent symptom scale(TESS).Results:The rates of marked improvement in Aripiprazole group and Risperidone group were 78.1% and 75.0% respectively.The extractor-ticospinal(EPS) tract reaction was more severe in risperidone group than in Aripiprazole group.Conclusion:Aripiprazole,as well as Risperidone,is one of effective antipsychotics and less EPS in the treatment of schizophrenia.

Key concepts: Aripiprazole, Risperidone, Schizophrenia (object-oriented programming), Positive and Negative Syndrome Scale, Medicine, Negative symptom, Internal medicine, Adverse effect

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical analysis of Aripiprazole in the treatment of schizophrenia — Research Paper | ScholarLens